MARIETTA, Ga., Sept. 18, 2014 /PRNewswire/ -- MiMedx Group, Inc.
(NASDAQ: MDXG), an integrated developer, processor and marketer of
patent protected regenerative biomaterials and bioimplants
processed from human amniotic membrane, announced today that it has
entered into a distribution agreement with Zimmer, Inc.
Through the agreement, MiMedx will provide its dehydrated
human amnion/chorion membrane ("dHACM") allograft products to
Zimmer to be marketed non- exclusively on a private label
basis.
The MiMedx dHACM allografts, processed utilizing the Company's
proprietary PURION® process, will be provided to Zimmer for
marketing under Zimmer's private-label. Through-out
the United States, Zimmer will
market and sell the private-labeled allografts to Zimmer customers
and end-users. The distribution agreement encompasses a range
of musculoskeletal applications to include reconstructive, sports
medicine, trauma, extremities and spinal applications.
Parker H. Petit, MiMedx Chairman
and CEO, said, "We are very pleased about the opportunity to
partner with Zimmer. This agreement will facilitate a sizable
expansion of the physicians and patients that will now have access
to our dHACM allografts. The breadth of the applications
included in the agreement and the large base of physicians,
hospitals and other medical facilities served by Zimmer will
enhance the presence of our allografts in the musculoskeletal
sector of the market."
"Zimmer has a stellar reputation and is a recognized leader in
bringing new technologies and applications to the forefront to
serve the reconstructive, sports medicine, trauma, extremities and
spinal markets," said Bill Taylor,
MiMedx President and COO. "Our goal is to reach as many
patients as possible that will benefit from the regenerative
properties of our allografts. Our relationship with Zimmer will
allow us to further the realization of that goal."
About Zimmer
Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer designs, develops,
manufactures and markets orthopaedic reconstructive, spinal and
trauma devices, dental implants, and related surgical
products. Zimmer has operations in more than 25 countries
around the world and sells products in more than 100
countries. Zimmer's 2013 sales were approximately
$4.6 billion. Zimmer is
supported by the efforts of more than 9,000 employees
worldwide.
About MiMedx
MiMedx® is an integrated developer, processor and marketer of
patent protected regenerative biomaterial products and bioimplants
processed from human amniotic membrane. "Innovations in
Regenerative Biomaterials" is the framework behind our
mission to give physicians products and tissues to help the body
heal itself. Our biomaterial platform technologies include
AmnioFix® and EpiFix®, our tissue technologies processed from human
amniotic membrane that is derived from donated placentas. Through
our donor program, mothers delivering full-term Caesarean section
births can elect in advance of delivery to donate the placenta in
lieu of having it discarded as medical waste. We process the human
amniotic membrane utilizing our proprietary PURION® Process, to
produce a safe and effective implant. MiMedx® is the leading
supplier of amniotic tissue, having supplied over 275,000
allografts to date for application in the Wound Care, Surgical,
Sports Medicine, Ophthalmic and Dental sectors of healthcare.
Safe Harbor Statement
This press release includes statements that look forward in time
or that express management's beliefs, expectations or hopes.
Such statements are forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995.
These statements include, but are not limited to the agreement
facilitating a sizable expansion of the physicians and patients
that have access to the Company's dHACM allografts, the effect of
the breadth of the applications included in the agreement and the
large base of physicians, hospitals and other medical facilities
served by Zimmer on the presence of the Company's allografts in the
musculoskeletal sector of the market, and the extent to which the
MiMedx relationship with Zimmer will allow the Company to further
the realization of its goal to reach as many patients as possible.
These statements are based on current information and belief, and
are not guarantees of future performance. Among the risks and
uncertainties that could cause actual results to differ materially
from those indicated by such forward-looking statements include
that the agreement may not facilitate a sizable expansion of the
physicians and patients that have access to the Company's dHACM
allografts, that the breadth of the applications included in the
agreement and the large base of physicians, hospitals and other
medical facilities served by Zimmer will not enhance the presence
of the Company's allografts in the musculoskeletal sector of the
market, that the MiMedx relationship with Zimmer will fail to
further the realization of the Company's goal to reach as many
patients as possible, and the risk factors detailed from time to
time in the Company's periodic Securities and Exchange Commission
filings, including, without limitation, its 10-K filing for the
fiscal year ended December 31,
2013. By making these forward-looking statements, the Company
does not undertake to update them in any manner except as may be
required by the Company's disclosure obligations in filings it
makes with the Securities and Exchange Commission under the federal
securities laws.
SOURCE MiMedx